In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma. In an interview with CURE, Dr. Lakshmi Nayak, a ...

Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma. The Food and Drug Administration (FDA) has approved ...

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...

We appreciate the kind words from Cohen 1 regarding the impact of our study but disagree with his recommendation in regard to methotrexate (MTX) dosing. We harbor reservations about ultra-high doses ...

Eliminating the label exclusion enables clinicians to consider axi-cel for relapsed/refractory primary CNS lymphoma, despite the disease not being explicitly added as an indicated population. Phase 1 ...

The risk for central nervous system (CNS) involvement is small in cases of diffuse large B-cell lymphoma (DLBCL) because only about 5% of patients develop it. But certain high-risk patients are even ...

A Prescription Drug User Fee Act target date of December 18, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

In our experience, patients' histories often note a neurologic prodrome years before PCNSL. These lingering illnesses, suggestive of multiple sclerosis or vitritis, might reflect polyclonal lymphoid ...

Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective ...

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive form of non-Hodgkin lymphoma, with a standard treatment approach typically involving R-CHOP. Despite overall favourable ...